Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download Regulation of Drug Marketing Introduction to Drug Law and
Transcript
Regulation of Drug Marketing Introduction to Drug Law and Regulation FDLI Workshop April 28-29, 2003 Teaneck, New Jersey Philip Katz Crowell & Moring LLP 1001 Pennsylvania Avenue, NW Washington, DC 20004 (202) 624-2660 [email protected] Drug Marketing • Advertising • Labeling • Other activities/statements • Sales force • Press releases • Securities filings 2 Drug Marketing • Advertising • Not well defined • Labeling • Label and “all other written, printed or graphic matter . . . accompanying” the drug • “Accompanying” defined broadly 3 Drug Marketing • Misbranded drugs • False or misleading labeling • Labeling lacks required information • Labeling lacks adequate directions for use or adequate warnings • Rx drug advertising lacks brief summary 4 Drug Marketing • False or misleading labeling and advertising • “Misleading” includes material omissions • Promoting unapproved uses • Inadequate brief summary • Lacking in fair balance 5 Drug Marketing • Unapproved new drugs • Defined by intended use • Look to advertising/labeling claims, statements, knowledge of other uses • Includes off-label uses of approved drugs 6 Drug Marketing • Unapproved new drugs • Reporting clinical trial results • Press releases • Securities filings • Describing narrow indications 7 Drug Marketing • Brief summary • True statement of information in brief summary relating to side effects, contraindications, and effectiveness • Exception for reminder ads • Exception for broadcast ads 8 Drug Marketing • Brief summary • Side effects, contraindications broadly defined • Information must be specific • Can’t fix false or misleading statements elsewhere in ad 9 Drug Marketing • Fair balance • Part of “true statement” in brief summary • Balance between information about effectiveness and that regarding side effects, contraindications • Look to scope, depth and detail of information 10 Drug Marketing • Lack of fair balance • Inadequately supported effectiveness or safety claims • Comparative claims not demonstrated by substantial evidence or substantial clinical experience • Selective, unrepresentative use of information 11 Drug Marketing • Reminder advertising • No need for brief summary • No representation or suggestion concerning safety, effectiveness or indications • Price ads only, if drug has boxed warning 12 Drug Marketing • Broadcast advertising • Information relating to major side effects and contraindications in audio or audio and visual parts of presentation • Exempt from brief summary if “adequate provision” made for disseminating approved labeling 13 Drug Marketing • August 1999 guidance on “adequate provision” • Toll-free number for access to labeling • Print ads or brochures • Website address • “See your doctor for more info” 14 Drug Marketing • FDA enforcement • Untitled letters or warning letters • Stop using the material • Corrective communications • Penalties for FDCA violations 15 Drug Marketing • FTC enforcement • OTC drug advertising • Different perspective, process, and results than FDA • Focus on false or misleading representations 16 Drug Marketing • FTC enforcement • Identify the representation • Determine whether it’s true and substantiated 17 Drug Marketing • Identifying the representation • Express and implied claims • Intent irrelevant • Reasonable interpretation by target audience 18 Drug Marketing • Truth and substantiation • Implied presence of substantiation • “Establishment” claims • True + false = false 19 Drug Marketing • Prescription Drug Marketing Act • Drug sample distribution • Written request from licensed practitioner • Requirements re request, receipt, verifying prescribing authority, inventory reconciliation, systems to prevent diversion, record-keeping • Significant penalties for violations 20 Drug Marketing • Issues of practical application • First Amendment • Direct-to-consumer promotion • Internet 21 Regulation of Drug Marketing Introduction to Drug Law and Regulation FDLI Workshop April 28-29, 2003 Teaneck, New Jersey Philip Katz Crowell & Moring LLP 1001 Pennsylvania Avenue, NW Washington, DC 20004 (202) 624-2660 [email protected]
